2622-26-6|Propericiazine|10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile|-范德生物科技公司

Propericiazine

NMR下载 COA and HPLC MSDS下载
names：
10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile
CAS号：
2622-26-6
MDL Number：
MF(分子式)： C21H23N3OS MW(分子量)： 365.49
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	10-[3-(4-hydroxypiperidin-1-yl)propyl]phenothiazine-2-carbonitrile
英文别名	Propericiazine; Periciazine; Propericiazine; PERICYAZINE; Neuleptil; Piperocyanomazine; Aolept; Aolept; Neuleptil; Neuleptyl; periciazine; pericyazine;
CAS号	2622-26-6
Inchi	InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
InchiKey	LUALIOATIOESLM-UHFFFAOYSA-N
分子式 Formula	C21H23N3OS
分子量 Molecular Weight	365.49
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Propericiazine(CAS:2622-26-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Propericiazine is a phenothiazine. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Ikeda H, Tsuji E, Matsubara T, Yukawa M, Fujisawa M, Yukawa E, Aki H.Incompatibility between propericiazine oral solution and tea-based drink. ChemPharm Bull (Tokyo). 2012;60(9):1207-1[1]PubMed PMID: 22976331.

[2]Cechin EM, Quevedo J, Barichello T, Machado-Vieira R, Gentil V, Kapczinski F.Dose-related effects of propericiazine in rats. Braz J Med Biol Res. 2003Feb;36(2):227-31. Epub 2003 Jan 29. PubMed PMID: 12563525.

[3] Ananth JV, Ban TA. A standard-controlled clinical study with propericiazine inschizophrenic patients. Psychopharmacol Bull. 1977 Jul;13(3):19-20. PubMed PMID:18754.

[4] Ananth JV, Salib M, Ban TA, Lehmann HE. Propericiazine in psychiatricemergencies. A controlled comparative study. Can Psychiatr Assoc J. 1972Apr;17(2):143-5. PubMed PMID: 4402542.

[5] Ropert R, Levy L, Bouyssou V, Ropert M. [Use of high doses of a majorneuroleptic, propericiazine, in the treatment of psychotic syndromes]. Encephale.1970 Sep-Oct;59(5):460-78. French. PubMed PMID: 4396004.

6: Lazzaroni Fossati F, Podestà F, Duillo MT. [A case of acute poisoning withpropericiazine in a pediatric patient]. J Econ Entomol. 1970 Aug;63(4):1077-83.Italian. PubMed PMID: 4395165.7: Seebandt G. [Experiences with propericiazine in the treatment of functionalpsychomotor disorders and states of restlessness in childhood].Arzneimittelforschung. 1970 Jul;20(7):937-9. German. PubMed PMID: 4394249.8: Lazzaroni Fossati F, Podestà F, Duillo MT. [A case of acute poisoning withpropericiazine in a pediatric patient]. Minerva Pediatr. 1970 May26;22(21):1077-83. Italian. PubMed PMID: 4395639.9: Agostinis G, Porati U, Maifreni F. [Critical review of the pharmacologicalaction of propericiazine in infantile preanesthesia. (Statistical study of 2075cases)]. Acta Anaesthesiol. 1970;31:Suppl:167-75. Italian. PubMed PMID: 4398517.10: Giménez Roldán S, Campos Castelló J. [Propericiazine and behavior disordersin neurological diseases in childhood and adolescence]. Arch Neurobiol (Madr).1969 Jul-Sep;32(3):331-46. Spanish. PubMed PMID: 4392861.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开